Medical management of abdominal aortic aneurysms;Medikamentöse Therapie bei Bauchaortenaneurysma

Vasa - European Journal of Vascular Medicine

Volumn 43, Issue 6, 2014, Pages 415-421

  Weiss, Norbert ^a   Rodionov, Roman N ^a   Mahlmann, Adrian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Abdominal aortic aneurysm; Cardiovascular risk; Medical therapy; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPRANOLOL; STRESS ACTIVATED PROTEIN KINASE; TELMISARTAN;

ABDOMINAL AORTA ANEURYSM; BLOOD PRESSURE; DISEASE COURSE; HUMAN; INCIDENCE; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

EID: 84924728298     PISSN: 03011526     EISSN: 16642872     Source Type: Journal    
DOI: 10.1024/0301-1526/a000388     Document Type: Review

References (43)

1. UKSAT Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346: 1445–52.
2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–701.
3. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Jr., Watson K, Wilson PW. 2013 ACC/ AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013.
4. Wilmink AB, Quick CR. Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 1998; 85: 155–62.
5. Bundesamt S. Gesundheitsbericht-erstattung des Bundes. 2014.
6. Diehm N. Abdominal aortic an-eurysm. Internist (Berl) 2009; 50: 972–8.
7. Iribarren C, Darbinian JA, Go AS, Fireman BH, Lee CD, Grey DP. Traditional and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the Kaiser multiphasic health checkup cohort study. Ann Epidemiol 2007; 17: 669–78.
8. Lederle FA, Johnson GR, Wilson SE, Chute EP, Hye RJ, Makaroun MS, Barone GW, Bandyk D, Moneta GL, Makhoul RG. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160: 1425–30.
9. Nordon IM, Hinchlif e RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011; 8: 92–102.
10. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Public Health 2004; 14: 343–9.
11. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and im plications for management. Arterioscler Thromb Vasc Biol 2006; 26: 2605–13.
12. Norman PE, Davis TM, Le MT, Golledge J. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association. Connect Tissue Res 2007; 48: 125–31.
13. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic an-eurysms. Cochrane Database Syst Rev 2012; 3: CD001835.
14. Kuivaniemi H, Platsoucas CD, Til-son MD, III. Aortic aneurysms: an immune disease with a strong genetic component. Circulation 2008; 117: 242–52.
15. Twine CP, Williams IM. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg 2011; 98: 346–53.
16. Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, Park HJ, Galper JB. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 2009; 29: 1764–71.
17. Lindholt JS, Heegaard NH, Vam-men S, Fasting H, Henneberg EW, Heickendorf L. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001; 21: 51–6.
18. Gotto AM, Jr. Role of Creative protein in coronary risk reduction: focus on primary prevention. Am J Cardiol 2007; 99: 718–25.
19. Schweitzer M, Mitmaker B, Obrand D, Sheiner N, Abraham C, Dostanic S, Meilleur M, Sugahara T, Chalifour LE. Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms. Vasc Endovascular Surg 2010; 44: 116–22.
20. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg 2012; 44: 287–92.
21. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Co-chrane Database Syst Rev 2012; 9: CD009536.
22. Sweeting MJ, Thompson SG, Brown LC, Powell JT. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012; 99: 655–65.
23. Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, Buxton MJ, Powell JT. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess 2013; 17: 1–118.
24. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson D W, Rutledge JC, Vergona R, Sullivan ME, Wang YX. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis 2005; 178: 9–17.
25. Iida Y, Xu B, Schultz GM, Chow V, White JJ, Sulaimon S, Hezi-Yamit A, Peterson SR, Dalman RL. Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One 2012; 7: e49642.
26. Kaschina E, Schrader F, Sommerfeld M, Kemnitz UR, Grzesiak A, Krikov M, Unger T. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens 2008; 26: 2361–73.
27. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368: 659–65.
28. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg 2010; 52: 1–4.
29. Diehm N, Baumgartner I. ACE inhibitors and abdominal aortic an-eurysm. Lancet 2006; 368: 622-3.
30. Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 2010; 103: 317–25.
31. Lindholt JS, Ashton HA, Scott RA. Indicators of infection with Chla-mydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J Vasc Surg 2001; 34: 212–5.
32. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM, Leinonen M, Kairaluoma MI, Saikku P. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499–505.
33. Karlsson L, Gnarpe J, Naas J, Ols-son G, Lindholm J, Steen B, Gnarpe H. Detection of viable Chlamydia pneumoniae in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2000; 19: 630–5.
34. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic an-eurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 1999; 878: 159–78.
35. Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001; 88: 1066–72.
36. Hogh A, Vammen S, Ostergaard L, Joensen JB, Henneberg EW, Lind-holt JS. Intermittent roxithromycin for preventing progression of small abdominal aortic aneurysms: long-term results of a small clinical trial. Vasc Endovascular Surg 2009; 43: 452–6.
37. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, Saikku P, Juvonen T. Use of doxy-cycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001; 34: 606–10.
38. Aoki H, Yoshimura K, Matsuzaki M. Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy. J Mol Med (Berl) 2007; 85: 1077–88.
39. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11: 1330–8.
40. Watanabe A, Ichiki T, Sankoda C, Takahara Y, Ikeda J, Inoue E, Tokunou T, Kitamoto S, Sunagawa K. Suppression of abdominal aortic aneurysm formation by inhibition of prolyl hydroxylase domain protein through attenuation of inflammation and extracellular matrix disruption. Clin Sci (Lond) 2014; 126: 671–8.
41. Takai S, Jin D, Yamamoto D, Li ZL, Otsuki Y, Miyazaki M. Significance of matrix metalloproteinase-9 inhibition by imidapril for prevention of abdominal aortic aneurysms in an-giotensin II type 1 receptor-knockout mice. J Pharmacol Sci 2013; 123: 185–94.
42. Lederle FA. The natural history of abdominal aortic aneurysm. Acta Chir Belg 2009; 109: 7–12.
43. Lederle FA, Johnson GR, Wilson SE, Ballard DJ, Jordan WD, Jr., Blebea J, Littooy FN, Freischlag JA, Bandyk D, Rapp JH, Salam AA. Rupture rate of large abdominal aortic aneurysms inpatients refusing or unfit for electiverepair. Jama 2002; 287: 2968–72.